comprehensive -WSS

comprehensive

author：leisure time 2025-09-03 09:38:19 - browse：5

Adam's take main illustration — Molly Ferguson/STAT

Some day-after thoughts on Bristol Myers Squibb acquiring Mirati Therapeutics:

A take-under deal feels meh for biotech sector sentiment.Bristol is paying $58 per share in cash for Mirati, which closed Friday at $60. Granted, Mirati was trading in the $30 range in September, so from there, the roughly 50% premium isn’t terrible. But as Mizuho strategist Jared Holz pointed out, investors would liked to have seen Mirati go for $75-$100 per share.

With the closely watched XBI biotech index down 13% for the year, every M&A deal helps improve sentiment, but this one — maybe just a little. Bristol is paying $4.8 billion in cash to acquire Mirati, or $3.7 billion after accounting for Mirati’s cash. It’s a small bolt-on acquisition for Bristol, which isn’t overpaying.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： See how much Covid

focus

WSS

Retired US general questions alleged Putin, Prigozhin meeting

Cord blood banking comes at a high cost to babies

How to increase colonoscopy rates? Looks like an AI can help

NIH fellows want a pay raise. Will that mean less money for grants?

Bulgari apologizes to China for listing Taiwan as a country after online backlash

New research casts further doubt on a common procedure used with IVF

leisure time

comprehensive

explore

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Why ADHD is under

Jerome Adams on the need for new antivirals for Covid

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

Medicare details structure of new drug price negotiation program

Retired US general questions alleged Putin, Prigozhin meeting

State Dept. review finds Biden bears some blame for Afghanistan failures

Beach reads and more: STAT's 2023 summer book list

Virginia high school admissions case could be legal follow

Study: Pain burden is higher in Black NFL players than white ones

focus

It's time to get medical device identifiers over the finish line

Insurance companies sue energy corporation after it was blamed for helping start Colorado wildfire

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

Charles Manson follower Leslie Van Houten released from prison after 53 years

Letters to First Opinion on caregivers, digital health, and more

Ionis drug prevents swelling attacks due to hereditary angioedema

hotspot

focus

explore

leisure time